Histidine Supplementation for Antitumor Immunity in Colorectal Cancer

The goal of this clinical study is to learn whether oral histidine supplementation may be safely used to support antitumor immune function during standard colorectal cancer treatment. Participants with colorectal cancer in the supplementation group will: Take 2g oral histidine once daily during standard colorectal cancer treatment; Provide blood samples before and after supplementation; Attend regular follow-up visits for laboratory tests, safety assessment, and treatment evaluation.

NCT Number	NCT07577505
Lead Sponsor	Jing-yuan Fang, MD, Ph. D Collaborators: Shanghai Punan Hospital of Pudong New District
Conditions	Colorectal Cancer
Enrollment	20 participants
Start Date	2026-05
Primary Completion	2026-12 (estimated)
Study Completion	2027-06 (estimated)
Updated on ClinicalTrials.gov	2026-05-11